Top 5 Undervalued Stocks To Buy Right Now

Below is my list of the top gold & silver mining stock takeover targets. None of them are producers, but they all have very lucrative properties. Plus, they are all undervalued. Most of them have very advanced projects.

Stock Name

Symbol (US)

Type

Share Price (US)

FD Shares

FD Mkt Cap (4/3/2017)

Alexco Resources

AXU

Silver

$1.52

108M

$164M

Aurvista Gold

ARVSF

Gold

$0.22

200M

$45M

Barkerville Gold Mining

Top 5 Undervalued Stocks To Buy Right Now: Turkcell Iletisim Hizmetleri AS(TKC)

Advisors’ Opinion:

  • [By Rich Smith]

    Shares of Turkish telecom Turkcell Iletisim Hizmetleri (NYSE:TKC) plummeted 10% to close at $4.42 per share on Thursday — then proceeded to slide more after-hours. Perhaps worse for investors trying to figure out how to react to this news: There was no obvious reason for the decline.

  • [By Dan Caplinger]

    The stock market lost ground on Monday, although the declines in some major benchmarks were more extreme than others. A budding financial crisis in Turkey once again captured the attention of investors, as the threat of rising tariffs and escalating diplomatic tension could drive a wedge through the North Atlantic Treaty Organization at a critical time for the geopolitical environment in the region. The repercussions of recent events involving Turkey echoed around the world, and some companies felt the tremors more sharply than others. First Majestic Silver (NYSE:AG), Turkcell Iletisim Hizmetleri (NYSE:TKC), and Transocean (NYSE:RIG) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Rich Smith]

    Turkish telco Turkcell Iletisim Hizmetleri (NYSE:TKC) became the latest victim of President Donald Trump’s favorite foreign policy tool — the tariff — this morning, falling 13.1% (as of 11:40 a.m. EDT) after the United States announced it would double the amount of tariffs imposed on steel and aluminum imported to the U.S. from Turkey.

  • [By Rich Smith]

    Turkish telco Turkcell Iletisim Hizmetleri (NYSE:TKC) closed up 11.6% on Thursday after the country’s central bank announced a big boost to interest rates — 24%, or 6.25 percentage points more than previously — boosting the Turkish lira’s value against the U.S. dollar for the third straight day.

Top 5 Undervalued Stocks To Buy Right Now: Apartment Investment and Management Company(AIV)

Advisors’ Opinion:

  • [By Max Byerly]

    Apartment Investment and Management (NYSE:AIV) had its hold rating reiterated by analysts at BMO Capital Markets. They currently have a $47.00 price target on the stock.

  • [By Stephan Byrd]

    News headlines about Apartment Investment and Management (NYSE:AIV) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Apartment Investment and Management earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the real estate investment trust an impact score of 46.6669103193152 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Ethan Ryder]

    Apartment Investment and Management (NYSE:AIV)‘s stock had its “hold” rating reiterated by equities researchers at BMO Capital Markets in a research report issued on Thursday. They currently have a $44.00 price target on the real estate investment trust’s stock. BMO Capital Markets’ price target suggests a potential upside of 3.92% from the company’s current price.

  • [By Max Byerly]

    Bank of Montreal Can increased its position in shares of Apartment Investment and Management Co (NYSE:AIV) by 91.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 184,796 shares of the real estate investment trust’s stock after buying an additional 88,340 shares during the period. Bank of Montreal Can owned about 0.12% of Apartment Investment and Management worth $7,818,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Apartment Investment and Management (AIV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Buy Right Now: Attunity Ltd.(ATTU)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Attunity Ltd (NASDAQ:ATTU) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $12.33.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Attunity (ATTU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Attunity (ATTU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Attunity (ATTU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Buy Right Now: Petroleum Resources Corporation(PEO)

Advisors’ Opinion:

  • [By Shane Hupp]

    Press coverage about Adams Natural Resources Fund (NYSE:PEO) has trended somewhat negative recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adams Natural Resources Fund earned a coverage optimism score of -0.09 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 48.0521373671292 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top 5 Undervalued Stocks To Buy Right Now: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By Shane Hupp]

    SG Americas Securities LLC acquired a new position in SAGE Therapeutics Inc (NASDAQ:SAGE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,233 shares of the biopharmaceutical company’s stock, valued at approximately $843,000.

  • [By Maxx Chatsko]

    Shares of Sage Therapeutics (NASDAQ:SAGE) soared more than 20% today after the company announced that the U.S. Food and Drug Administration will allow an expedited development program for one of its most promising drug candidates.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Joseph Griffin]

    Stevens Capital Management LP bought a new stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 3,223 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *